REPL
Replimune Group, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 2 ▼ 1 insider sell $52.1K at $8.01
- May 18 ▼ 6 insiders sell $474.1K at $5.08
- May 29 ▲ Replimune announced alignment with the FDA on a path forward for res…
- May 30 ▲ Replimune presented 3-year landmark overall survival data from the I…
- Jun 1 ▼ 1 insider sell $110.9K at $9.24
- Aug 7 ▲ Wedbush upgrades
- Aug 10 to Aug 17 ▼ 2 days of insider sells: $1.0M by 4 insiders, avg $13.12
- Aug 11 ▲ 1 insider buy $33.0M at $12.06
- Aug 14 ▲ Replimune reported fiscal Q1 2027 results with an in-line net loss o…
- Aug 19 Replimune insiders show a mixed cluster: Baker Bros. (10% owner) bou…
- Sep 19 M&A: REPL Stockholders with Significant Losses Should Contact R…
- Nov 2 to Nov 9 ▼ 2 days of insider sells: $521.9K by 2 insiders, avg $19.55
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $33.0M at an average $12.06. 8 insiders sold $2.2M. Price is 78% above their cost.
- InstitutionsBULLISH
Q3 2026: 30 added (2 new), 19 trimmed or exited. Largest new: Marshall Wace $50.5M.
- AnalystsBULLISH
13 of 15 rate it Buy or better.
- Short sellersSTEADY
Short interest +6.2% to 24.61M shares. 8.3 days to cover, ≈26.0% of shares.
- TrendUPTREND
44% above its 50-day average. New closing high $23.28 on Nov 10.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 24.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | NEW | $50.5M |
| Artisan Partners Limited Partnership | DOUBLED | $29.3M |
| MORGAN STANLEY | DOUBLED | $28.3M |
| Nuveen, LLC | DOUBLED | $18.0M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $11.3M |
| JANE STREET GROUP, LLC | TRIM | $10.1M |
| FMR LLC | TRIM | $8.1M |
| BARCLAYS PLC | ADD | $4.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Oct 29, 2026 | Leerink Partners MAINTAIN | Outperform |
| Aug 26, 2026 | JP Morgan MAINTAIN | Overweight |
| Aug 7, 2026 | JP Morgan MAINTAIN | Overweight |
| Aug 7, 2026 | Wedbush UPGRADE | Outperform |
| Aug 4, 2026 | Leerink Partners UPGRADE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
SLATTERY JOSEPH P Director Nov 9, 2026 | SELL | $113.4K |
Dhingra Kapil Director Nov 2, 2026 | SELL | $408.5K |
Dhingra Kapil Director Nov 2, 2026 | EXERCISE | $75.5K |
Astley-Sparke Philip Director Aug 20, 2026 | GIFT | 50,000 sh |
Hill Emily Luisa Chief Financial Officer Aug 17, 2026 | SELL | $132.2K |
BAKER BROS. ADVISORS LP Director Aug 11, 2026 | BUY | $1.5M |
BAKER BROS. ADVISORS LP Director Aug 11, 2026 | BUY | $31.5M |
Xynos Konstantinos Chief Medical Officer Aug 10, 2026 | SELL | $148.5K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Jul 30, 2026 | Resumption Scheduled | Resumed |
SecBot reports
29 filings · 3 press releases · 8 bullish · 5 bearish · 2 mixed · 14 neutral- NEUTRAL SC 13G/ANov 16, 2026
RTW Investments, LP filed an amended Schedule 13G disclosing a 9.0% passive stake in Replimune Group as of September 30, 2026, representing 8,491,525 shares. This is a significant increase from the prior filing (not provided in this document), but remains a routine passive investment update with…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL CLUSTERNov 10, 2026
Two Replimune directors sold a total of $522K in open-market sales over a week, with Kapil Dhingra…
The dollar amount is negligible relative to market cap, so no material signal. Monitor next quarter for TUDRIQEV revenue traction and any larger insider sales.
- NEUTRAL SC 13GNov 10, 2026
State Street Corp filed a Schedule 13G disclosing a 4.4% passive stake in Replimune Group as of…
Monitor for any future 13D conversion or stake increase above 5%, but this filing is a routine passive disclosure by a large custodian. The stake is consistent with State Street's role as an index…
- NEUTRAL 144Nov 9, 2026
Director Joseph P. Slattery filed a Form 144 notice of intent to sell 5,200 shares of Replimune…
The proposed sale is small and by a director, not the CEO or CFO. Monitor for any subsequent Form 4 filings to confirm execution, but this filing alone does not signal a material change in insider…
All REPL filing & press-release reports (32)
- SC 13G/A reportNov 16, 2026
- CLUSTER reportNov 10, 2026
- SC 13G reportNov 10, 2026
- 144 reportNov 9, 2026
- SC 13G/A reportNov 9, 2026
- 10-Q/A reportNov 6, 2026
- INST-CLUSTER reportNov 4, 2026
- 144 reportNov 3, 2026
- 144 reportNov 2, 2026
- 144 reportOct 30, 2026
- 144 reportOct 28, 2026
- 8-K reportOct 28, 2026
- PRESS-RELEASE reportOct 28, 2026
- PRESS-RELEASE reportOct 22, 2026
- CLUSTER reportAug 19, 2026
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 12, 2026
- 424B5 reportAug 10, 2026
- 8-K reportAug 10, 2026
- 8-K reportAug 6, 2026
- 8-K reportJul 30, 2026
- S-3/A reportJul 24, 2026
- 8-K reportJun 29, 2026
- PRESS-RELEASE reportJun 29, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportMay 31, 2026
- PRESS-RELEASE reportMay 30, 2026
- 8-K reportMay 29, 2026
- PRESS-RELEASE reportMay 29, 2026
- CLUSTER reportMay 20, 2026